Value Chain Analysis Case Study

Novartis' Generic Drug Business: The New Growth Driver

OR

Abstract:
In 2003, to lay more emphasis on its generics business, Novartis rebranded its entire generics product lines under the Sandoz brand, the brand that had merged with Ciba-Geigy to form Novartis in 1996. In February 2005, Novartis acquired Germany-based generic drugs company, Hexal, and its affiliate, Eon Labs, for enhancing its capability to grab a 10% market share in the US$100 billion global generics market by 2010

Pedagogical Objectives:

• To highlight the growth strategies of Novartis in the generics business
• To discuss the strategies adopted by Novartis to face the twin challenges of low prices and high competition in the global generic drug industry.

Keywords : Novartis; Sandoz; Generics; Strategy; Branded drugs; Patent; Generics market; Growth Strategies Case Study; Pharmaceutical industry; USA; Germany; Growth; Eon; Hexal; Sabex

Contents:

• The Generic Drug Business of Novartis
• Novartis' Strategy to be a Leader in Generics Market
• The Payoffs